Curium wins patent case, clears path for GEP-NET therapy

Curium prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications over Curium's Lutetium Lu 177 dotatate product. The Delaware U.S. District Court ruled all relevant patent claims invalid and not infringed. The decision allows Curium to launch its therapy for GEP-NETs in the U.S.